LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Capital reiterated a Buy rating on the stock and raised the price target from $39 to $45. Earlier, on January 14, Kelsey Goodwin from Piper Sandler reiterated a Buy rating on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) with a price target of $40. ?Analysts at Piper Sandler noted that the bullish rating is based on the company's Palazestrant. Palazestrant is a potential best-in-class for treating ER+/HER2- breast cancer. The firm highlighted the drug's complete ER antagonism and ER degradation ability. These capabilities are expected to make the drug an upcoming treatment in the huge breast cancer market. ?In addition, the firm highlighted that the company is expecting multiple phase 3 trials in 2026, which are expected to add further upside to the stock. Piper Sandler expects Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) to launch Palazestrant by next year. ?Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused on the development of treatments for patients with breast cancer and other
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Oncology Announces Departure of Chief Operating and Financial OfficerGlobeNewswire
- JPM26: Roche's rejuvenation strategy for the oncology and haematology portfolio [Yahoo! Finance]Yahoo! Finance
- Olema Insider Sells $8 Million in Shares After 300% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (NASDAQ:OLMA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]Yahoo! Finance
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 1/30/26 - Form 8-K
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- OLMA's page on the SEC website